TY  - RPRT
TI  - The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC).
AU  - Hye Sung Kim
AU  - Li Zhang
AU  - J Nicholas Bodor
AU  - Margie L Clapper
AU  - Hossein Borghaei
AU  - Martin J Edelman
AU  - Yunyun Zhou
AU  - Mitchell Cheung
AU  - Joseph Treat
PY  - 2026
DO  - 10.1016/j.lungcan.2026.109582
UR  - https://pubmed.ncbi.nlm.nih.gov/42660014/
ID  - 42660014
ER  -